{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T05:09:29Z","timestamp":1778389769266,"version":"3.51.4"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The CD33 rs12459419 (C&gt;T; Ala14Val) single-nucleotide polymorphism (SNP) has been reported to modulate treatment response and survival in pediatric patients with acute myeloid leukemia (AML) receiving gemtuzumab ozogamicin (GO), an anti-CD33 antibody linked to the cytotoxic compound calicheamicin. However, it remains unclear whether this SNP also affects CD33 expression on leukemic blasts. Moreover, its prognostic significance in adult AML patients treated with standard chemotherapy without GO has not been investigated. In this study, we retrospectively genotyped 184 adult AML patients who received standard induction chemotherapy for the CD33 rs12459419 SNP genotype and collected CD33 expression data. The observed genotype distribution was 46% (n = 85) CC, 43% (n = 79) CT, and 11% (n = 20) TT. CD33 expression was detected in significantly higher proportions of leukemic blasts in patients with the CC genotype than those with the TT genotype (p = 0.0009). A similar trend was observed between the CT and TT genotypes (p = 0.06). No significant differences in clinical outcome were detected among the three genotype cohorts. Grouping CC and CT genotypes together based on their similar CD33 expression and comparing them to patients with the TT genotype also revealed no differences in overall survival (OS), event-free survival (EFS), or relapse-free survival (RFS). Using a proportion of 90% CD33-positive blasts to define high versus low expression groups also failed to identify a meaningful impact on OS, EFS, or RFS, either across genotypes or independent of genotype. In conclusion, our findings indicate that the CD33 rs12459419 SNP does not affect outcomes or survival in adult AML patients receiving standard chemotherapy in the absence of GO. Furthermore, no association was seen between CD33 expression and clinical outcomes between the three genotypes. To our knowledge, this is the first study to investigate the prognostic impact of the CD33 rs12459419 SNP per se on outcome and survival in adult AML patients treated with chemotherapy without GO. Validation in larger patient cohorts is required to conclusively rule out a prognostic role of the CD33 rs12459419 SNP in AML.<\/jats:p>","DOI":"10.3390\/ijms27094050","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:50:01Z","timestamp":1777618201000},"page":"4050","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin"],"prefix":"10.3390","volume":"27","author":[{"given":"Sophie","family":"Helfenstein","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Shaforostova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"},{"name":"Department for Biomedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Noelle","family":"Kronig","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Legros","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2016.12.001","article-title":"Consolidation with Autologous Stem Cell Transplantation in First Remission Is Safe and Effective in AML Patients above 65 Years","volume":"53","author":"Heini","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s41409-019-0762-3","article-title":"Excellent Outcome after Consolidation with Autologous Transplantation in Patients with Core Binding Factor Acute Myeloid Leukemia","volume":"55","author":"Sula","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/leu.2014.332","article-title":"Comparative Therapeutic Value of Post-Remission Approaches in Patients with Acute Myeloid Leukemia Aged 40\u201360 Years","volume":"29","author":"Cornelissen","year":"2015","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and Levels of Cell Surface Expression of CD33 and CD123 in Acute Myeloid Leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_7","first-page":"3132941","article-title":"No Evidence That CD33 Rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group","volume":"2022","author":"Sargas","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy in Adult Patients with Acute Myeloid Leukaemia: A Meta-Analysis of Individual Patient Data from Randomised Controlled Trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Martinez Flores, D., Akhoundova, D., Seipel, K., Legros, M., Kronig, M.-N., Daskalakis, M., Bacher, U., and Pabst, T. (2024). Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071616"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 Is a Predictive Factor for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 Expression Levels in Acute Myeloid Leukemia Cells Carrying the Nucleophosmin (NPM1) Mutation","volume":"96","author":"Raponi","year":"2011","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report from Randomized Phase III Children\u2019s Oncology Group Trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-12-3115","article-title":"Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin\u2013Containing Chemotherapy","volume":"19","author":"Mortland","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1080\/10428194.2017.1421756","article-title":"CD33 Splicing SNP Regulates Expression Levels of CD33 in Normal Regenerating Monocytes in AML Patients","volume":"59","author":"Lamba","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3324\/haematol.2018.202069","article-title":"Relationship between CD33 Expression, Splicing Polymorphism, and in Vitro Cytotoxicity of Gemtuzumab Ozogamicin and the CD33\/CD3 BiTE\u00ae AMG 330","volume":"104","author":"Laszlo","year":"2019","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1002\/ajh.25854","article-title":"Impact of CD33 and ABCB1 Single Nucleotide Polymorphisms in Patients with Acute Myeloid Leukemia and Advanced Myeloid Malignancies Treated with Decitabine plus Gemtuzumab Ozogamicin","volume":"95","author":"Short","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2017-08-802157","article-title":"No Evidence That CD33 Splicing SNP Impacts the Response to GO in Younger Adults with AML Treated on UK MRC\/NCRI Trials","volume":"131","author":"Gale","year":"2018","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-019-0771-0","article-title":"CD33 Splice Site Genotype Was Not Associated with Outcomes of Patients Receiving the Anti-CD33 Drug Conjugate SGN-CD33A","volume":"12","author":"Stanchina","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.3324\/haematol.2021.278894","article-title":"Cluster of Differentiation 33 Single Nucleotide Polymorphism Rs12459419 Is a Predictive Factor in Patients with Nucleophosmin1-Mutated Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin","volume":"106","author":"Teich","year":"2021","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.3324\/haematol.2021.279043","article-title":"Time to Reconsider CD33 Single Nucleotide Polymorphism in the Response to Gemtuzumab Ozogamicin","volume":"106","author":"Lamba","year":"2021","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12185-024-03814-z","article-title":"High-Dose Cytarabine plus Gemtuzumab Ozogamicin as Consolidation Therapy in Patients with Favorable- or Intermediate-Risk Acute Myeloid Leukemia","volume":"120","author":"Oya","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamicin Containing Chemotherapy in Childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The Level of Blast CD33 Expression Positively Impacts the Effect of Gemtuzumab Ozogamicin in Patients with Acute Myeloid Leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liu, J., Tong, J., and Yang, H. (2022). Targeting CD33 for Acute Myeloid Leukemia Therapy. BMC Cancer, 22.","DOI":"10.1186\/s12885-021-09116-5"},{"key":"ref_25","unstructured":"Motulsky, H.J. (2025, November 10). GraphPad Statistics Guide. Available online: https:\/\/www.graphpad.com\/guides\/prism\/8\/statistics\/index.htm."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/4050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:22:27Z","timestamp":1778386947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/4050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27094050"],"URL":"https:\/\/doi.org\/10.3390\/ijms27094050","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}